Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone Augmentation in Depressed Partial Responders
NCT00178854Phase 4Withdrawn
- Sponsor
- Vanderbilt University Medical Center
- Start
- May 2004
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of risperidone in major depressive disorder (MDD), sponsored by Vanderbilt University Medical Center. Primary endpoint: Cerebrospinal Fluid Chemical Levels. Planned start May 2004; status: withdrawn.
02
Drugs
risperidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00178854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00178854.